Sarcosine
In clinical developmentRecent clinical, regulatory, research and industry developments relating to this drug.
Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome.
N-methyl-D-aspartate (NMDA) Enhancers' Benefit to Schizophrenia Treatment
N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder
NMDA Enhancers in the Treatment of Schizophrenia
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Frontiers in immunology1
- Cohen Tervaert JW1
- Elahi S1
- Li L1
- Luo X1
- Osman M1
- Redmond D1
- Saito S1
- Shahbaz S1
- Li Ka Shing Institute of Virology1
- School of Dentistry1
- The Metabolomics Innovation Centre1
- University of Alberta1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Sarcosine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials